Open Label Single Center Pilot Study to Study The Effects of Metreleptin Administration in Patients With Type 1 Diabetes Mellitus ( T1DM ).
Phase of Trial: Phase I
Latest Information Update: 06 May 2016
At a glance
- Drugs Metreleptin (Primary) ; Insulin
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 02 May 2016 Primary endpoint of safety and tolerability of leptin removed and time frame for endpoint-Change in HgbA1c reduced from 5 months to 3 months. Trial focus changed.
- 23 Jun 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.